Vertex Pharmaceuticals Inc / MA (VRTX) insider trading
Every open-market stock purchase and sale by Vertex Pharmaceuticals Inc / MA executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Healthcare.
Insider activity at a glance
- Duncan McKechnie (C-suite exec) and 2 others sold $2M in the last 90 days.
- Last insider buy: Reshma Kewalramani (CEO), $2.2M, 14 months ago.
Last 12 months: insiders bought $0 (0 buys) and sold $155M (53 sales). Last close $515.44 on Sep 11, 2026.
Recent VRTX insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Sep 8, 2026 | Jasper van Grunsven (VP) | Bought (not open market) | — |
| Aug 28, 2026 | Kristen Ambrose (C-suite exec) | Bought (not open market) | — |
| Aug 27, 2026 | Bruce I Sachs (Director) | Sold (not open market) | — |
| Jul 21, 2026 | Ourania Tatsis (VP) | Bought (not open market) | — |
| Jul 21, 2026 | Amit Sachdev (VP) | Bought (not open market) | — |
| Jul 15, 2026 | Bruce I Sachs (Director) | Bought (not open market) | $47.5K |
| Jul 15, 2026 | Alan M Garber (Director) | Bought (not open market) | $15K |
| Jul 2, 2026 | Duncan McKechnie (C-suite exec) | Sold | $800K |
| Jul 2, 2026 | Ourania Tatsis (VP) | Sold | $787K |
| Jul 1, 2026 | Joy Liu (C-suite exec) | Sold | $416K |
| Jun 26, 2026 | Carmen Bozic (C-suite exec) | Sold | $288K |
| Jun 18, 2026 | Carmen Bozic (C-suite exec) | Sold | $471K |
| Jun 15, 2026 | Carmen Bozic (C-suite exec) | Sold | $1.8M |
| Jun 5, 2026 | Carmen Bozic (C-suite exec) | Sold | $785K |
| Jun 1, 2026 | Joy Liu (C-suite exec) | Sold | $364K |
| May 29, 2026 | Carmen Bozic (C-suite exec) | Sold | $888K |
| May 15, 2026 | Carmen Bozic (C-suite exec) | Sold | $614K |
| May 15, 2026 | Mark E. Bunnage (C-suite exec) | Sold | $15K |
| May 12, 2026 | Carmen Bozic (C-suite exec) | Sold | $3.1M |
| May 4, 2026 | Sangeeta N. Bhatia (Director) | Sold | $135K |
| May 1, 2026 | Joy Liu (C-suite exec) | Sold | $469K |
| May 1, 2026 | Suketu Upadhyay (Director) | Bought (not open market) | — |
| May 1, 2026 | Jennifer Schneider (Director) | Sold (not open market) | — |
| May 1, 2026 | Michel Lagarde (Director) | Bought (not open market) | — |
| May 1, 2026 | Nancy Thornberry (Director) | Bought (not open market) | — |
Who's trading VRTX
- Jasper van Grunsven, VP: other filings, last Sep 8, 2026
- Kristen Ambrose, C-suite exec: sold $2M (5 sales), last Aug 28, 2026
- Bruce I Sachs, Director: other filings, last Aug 27, 2026
- Amit Sachdev, VP: sold $28.4M (9 sales), last Jul 21, 2026
- Ourania Tatsis, VP: sold $6.5M (8 sales), last Jul 21, 2026
- Alan M Garber, Director: other filings, last Jul 15, 2026
- Duncan McKechnie, C-suite exec: sold $5.7M (5 sales), last Jul 2, 2026
- Joy Liu, C-suite exec: sold $2.1M (5 sales), last Jul 1, 2026
- Carmen Bozic, C-suite exec: sold $11.3M (10 sales), last Jun 26, 2026
- Mark E. Bunnage, C-suite exec: sold $3M (5 sales), last May 15, 2026
- Sangeeta N. Bhatia, Director: sold $268K (2 sales), last May 4, 2026
- Suketu Upadhyay, Director: other filings, last May 1, 2026
- Lloyd Carney, Director: other filings, last May 1, 2026
- Jennifer Schneider, Director: other filings, last May 1, 2026
- Nancy Thornberry, Director: other filings, last May 1, 2026
Get free alerts when an insider at Vertex Pharmaceuticals Inc / MA files a new trade →